Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability

Abstract

PARP7 has been recently identified as an effective drug target due to its specific role in tumor generation and immune function recovery. Herin, we report the discovery of compound 8, which contained a tricyclic fused ring, as a highly selective PARP7 inhibitor against other PARPs. In particular, compound 8 strongly inhibits PARP7 with an IC₅₀ of 0.11 nM, and suppresses the proliferation of NCI-H1373 lung cancer cells with an IC₅₀ of 2.5 nM. Compound 8 exhibits a favorable pharmacokinetic profile with a bioavailability of 104 % in mice, and 78 % in dogs. Importantly, daily treatment of 30 mg/kg of 8 induced 81.6 % tumor suppression in NCI-H1373 lung xenograft mice tumor models, which is significantly better than the clinical candidate, RBN-2397. These intriguing features highlight the promising advantages of 8 as an antitumor agent.

Keywords: ADME-T; Cyclization; PARP7; Pharmacokinetic; Selectivity.